| Parameter | Base-case value | Range | Distribution | Source |
| Treatment costs (CNY per cycle) |
|
|
|
|
| Nivolumab | 82561.32 | 66049.056 - 99073.584 | GAMMA | MENET |
| XELOX | 6681.99 | 5345.595 - 8018.392 | GAMMA | MENET |
| FOLFOX | 19024.40 | 15219.523 - 22829.285 | GAMMA | MENET |
| Disease management costs |
|
|
|
|
| Drug administration and hospitalization | 402 | 321.6 - 482.4 | GAMMA | Han Jia-qi et al., [11] |
| Imaging examination (CT or MRI) | 800 | 640 - 960 | GAMMA | Han Jia-qi et al., [11] |
| PD - L1 test | 1410 | 1128 - 1692 | GAMMA | Han Jia-qi et al., [11] |
| Adverse event management costs (per event) | ||||
| Anemia | 3789.40 | 3031.52 - 4547.28 | GAMMA | Liu Guo-qiang et al., [13] |
| Neutrophil count decreased | 3381 | 2704.8 - 4057.2 | GAMMA | Tan Chongqing et al., [12] |
| Lipase increased | 298 | 238.4 - 357.6 | GAMMA | MENET |
| Incidence of adverse events in nivolumab plus chemotherapy group | ||||
| Anemia | 0.06 | 0.048 - 0.072 | BATA | CheckMate649 [6] |
| Neutrophil count decreased | 0.257 | 0.206 - 0.308 | BATA |
|
| Lipase increased | 0.058 | 0.046 - 0.069 | BATA |
|
| Incidence of adverse events in chemotherapy alone group | ||||
| Anemia | 0.027 | 0.022 - 0.033 | BATA |
|
| Neutrophil count decreased | 0.209 | 0.167 - 0.25 | BATA |
|
| Lipase increased | 0.021 | 0.017 - 0.025 | BATA |
|
| The cost of Subsequent therapy |
|
|
|
|
| In nivolumab plus chemotherapy group | 17054.49 | 13643.596 - 20465.394 | GAMMA | CheckMate649 [6] |
| In chemotherapy alone group | 21582.01 | 17265.608 - 25898.412 | GAMMA |
|
| Health state utility values |
|
|
|
|
| PFS | 0.797 | 0.638 - 0.956 | BATA | T Shiroiwa [14] |
| PD | 0.577 | 0.462 - 0.692 | BATA |
|
| Discount rate | 5% | 0% - 8% | China Guidelines for Pharmacoeconomics Evaluations (2020) [7] | |